Investment Thesis
Pre-revenue pharmaceutical company with accelerating cash burn (-6.0M annually) and operational losses (-2.5M), providing less than one year of runway at current burn rate despite strong liquidity. The +149M net income is a one-time event that masks fundamentally unprofitable operations with no revenue generation.
Strengths
- Strong liquidity position with $6.4M cash representing 88.9% of total assets
- Zero debt with minimal liabilities ($645K), eliminating refinancing risk
- Positive cash position provides buffer to fund clinical development activities
Risks
- Severe cash burn of $6.0M annually with no revenue offsets, limiting operational runway to ~12 months
- Net income of $149M contradicts negative operating income and cash flow, indicating non-operational one-time gain masking true business performance
- Complete lack of revenue generation with no evidence of commercial product traction or market validation
- Data quality issues evident from impossibly high ROE (3750.6%) and ROA (2071.3%), raising reliability concerns
Key Metrics to Watch
- Quarterly cash burn rate and cash position trajectory
- Clinical trial progress and regulatory milestones for pipeline assets
- Revenue generation timeline and first commercial product approval
Financial Metrics
Revenue
N/A
Net Income
149.0M
EPS (Diluted)
$0.64
Free Cash Flow
-6.0M
Total Assets
7.2M
Cash
6.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
3,750.6%
ROA
2,071.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
11.00x
Quick Ratio
11.00x
Debt/Equity
0.00x
Debt/Assets
9.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-10T19:30:25.356845 |
Data as of: 2025-12-31 |
Powered by Claude AI